STK16-IN-1

STK16-IN-1 is a STK16 kinase inhibitor with an IC₅₀ of 295 nM. IC50 & Target: IC50: 295 nM (STK16)^[1] In Vitro: STK16-IN-1, which exhibits potent inhibitory activity against STK16 kinase (IC₅₀=0.295 μM) with excellent selective across the kinome as assessed using the KinomeScanTM profiling assay. STK16-IN-1 inhibits mTOR kinase with an IC₅₀ of 5.56 μM. In MCF-7 cells, treatment with STK16-IN-1 results in a reduction in cell number and accumulation of binucleated cells, which can be recapitulated by RNAi knockdown of STK16. Co-treatment of STK16-IN-1 with chemotherapeutics such as cisplatin, doxorubicin, colchicine and paclitaxel results in a slight potentiation of the anti-proliferative effects of the chemotherapeutics. STK16-IN-1 provides a useful tool compound for further elucidating the biological functions of STK16)^[1].